Caris pushes capacity as clinical testing volume accelerates
- Q3 2026 revenue grew 27 percent year over year to $275 million.
- The company posted its sixth consecutive quarter of positive adjusted EBITDA.
- Free cash flow turned negative as the company spent heavily on inventory to prevent back orders.
- Management raised full year revenue guidance to a range of $1.04 billion to $1.05 billion.
- The main risk is whether the company can build enough capacity for new product launches.
Scaling past breakeven
Caris is showing real scaling power. In Q3 2026, revenue rose 27 percent year over year to $275 million. The company marked its sixth straight quarter of positive adjusted EBITDA and management raised full year revenue guidance to over $1 billion.
The bull case rests on volume growth and new products. Clinical volume accelerated to 61,500 cases in the third quarter, up 21 percent year over year. The company also entered the monitoring market with Caris Assure Therapy Response Monitoring and plans to launch Caris Confirm for minimal residual disease in December 2026.
The bear case focuses on growing pains and cash burn. Near-term cash generation took a hit in Q3, with free cash flow dropping to a negative $39.7 million. Management made deliberate inventory investments to build capacity for the Caris Detect launch and prevent back orders.
The next clear watch items are the scaling pace for Caris Detect, the December rollout for Caris Confirm, and the expected interim readout for the ACHIEVE 2 study in the first quarter of 2027.
Tests first, data second
Caris makes most of its money by selling molecular profiling services. These tests read cancer samples from tissue or blood to help doctors pick treatments. In Q3 2026, molecular profiling services produced $262.7 million of revenue.
The second business sells pharma research and development services. Drug companies use Caris data, testing, and bioinformatics to study cancer and improve drug programs. This part of the business contributed $12.7 million in the third quarter.
The model works best when test volumes rise and each test earns strong reimbursement. The major risk is execution. If new products face manufacturing limits or back orders, revenue growth could stall even with high demand.
A cancer testing stack
MI Profile
MI Profile is the tissue-based platform and generates most of the company revenue.
Caris Assure
Caris Assure is the universal blood-based profiling platform used for therapy selection.
Caris Detect
Launched in June 2026, this multi-cancer early detection assay is a major catalyst but faces near-term capacity limits.
Caris Confirm
A whole-genome minimal residual disease assay scheduled to launch in December 2026.
ChromoSeq
Launched in April 2026, this therapy selection assay features whole genome and whole transcriptome technology.
Biopharma R&D services
Caris works with drug companies on testing, data, and discovery projects. This smaller business makes the data platform more valuable.
Mostly clinical testing
The mix is from Q3 2026 revenue. Molecular profiling is the clear revenue base, so any reimbursement or capacity change in that line matters a lot.
What could break
Capacity constraints
High impact · Medium oddsManagement noted that near-term demand for the newly launched Caris Detect could outstrip the rollout pace. The company spent heavily on inventory in Q3, driving free cash flow negative, but back orders remain a real risk.
Reimbursement pressure
High impact · Medium oddsHigher reimbursement rates have helped lift the average selling price for older tests. If payers cut rates or limit coverage for new platforms like ChromoSeq, growth could slow even if test volume keeps rising.
Debt-funded expansion misfires
Medium impact · Low oddsCaris has access to up to $1.2 billion in debt capacity. That gives it room to expand or buy assets, but it raises the cost of a bad deal if growth does not follow.
In one breath
What does Caris Life Sciences do?
Caris sells cancer molecular profiling tests. These tests study tumor tissue or blood so doctors can better match patients with treatments.
How does Caris make money?
Most revenue comes from molecular profiling services sold for clinical use. A smaller part comes from pharma research and development services, where drug companies pay for Caris testing and data.
Is Caris profitable?
The company reported its sixth consecutive quarter of positive adjusted EBITDA in Q3 2026. However, free cash flow turned negative recently as the company spent heavily to build inventory.
What is the biggest catalyst for CAI stock?
The clearest near-term catalysts are the scaling of the newly launched Caris Detect, the December 2026 launch of Caris Confirm for minimal residual disease, and trial readouts in 2027.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Caris Life Sciences, Inc. in Finn's Biotechnology industry ranking.

